Product Information
IRBESARTAN 300 MG TABLET is a generic product labeled by Jubilant Cadista Pharmaceuticals Inc., priced at $0.1794 per EA under NDC 59746044990. Its NADAC has been published 483 times since Dec 9, 2015.
FDA first approved this application on Feb 23, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Jubilant Cadista Pharmaceuticals Inc.NDC
59746044990
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
2/19/2025
Active Ingredients
IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA203534FDA Approved
2/23/2015
TE Code
AB
On Market Since
2/24/2015
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN 300 MG TABLET has been published 483 times since Dec 9, 2015, and over the history we have for it it has declined 32.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1794 per EA |
|---|---|
| All-time high | $0.3794 (Jun 10, 2020) |
| All-time low | $0.1480 (May 22, 2024) |
| Median price | $0.2633 |
| Average price | $0.2627 |
| Largest weekly change | +33.1% (Aug 21, 2024) |
| Weeks tracked | 483 |
| Tracking since | Dec 9, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-15.9%
5Y
-44.3%
All
-32.3%
Last surveyed Mar 5, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of IRBESARTAN 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN 300 MG TABLET, manufactured by Jubilant Cadista Pharmaceuticals Inc., is $0.1794 per EA (NDC 59746044990), effective Mar 5, 2025.
How has the price of IRBESARTAN 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for IRBESARTAN 300 MG TABLET has declined 32.3%. It has been tracked across 483 weekly CMS publications since Dec 9, 2015.
What are the highest and lowest recorded NADAC prices for IRBESARTAN 300 MG TABLET?
Since Dec 9, 2015, the NADAC for IRBESARTAN 300 MG TABLET has ranged from a low of $0.1480 (May 22, 2024) to a high of $0.3794 (Jun 10, 2020), with a median of $0.2633 per EA.
Are there cheaper alternatives to IRBESARTAN 300 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN 300 MG TABLET, is $0.1555 per EA — about 13% below IRBESARTAN 300 MG TABLET.
Who manufactures IRBESARTAN 300 MG TABLET?
IRBESARTAN 300 MG TABLET (NDC 59746044990) is labeled by Jubilant Cadista Pharmaceuticals Inc., and CMS classifies it as a generic product.